Topical tirbanibulin (Klisyri) for actinic keratoses with downward-directed growth
Investigation of the Efficacy and Tolerability of Topical Applied Tirbanibulin on Actinic Keratoses With Downward-directed Proliferation Patterns
We will test whether applying topical tirbanibulin (Klisyri) can reduce downward-directed proliferation of actinic keratoses on the scalp or face in adults.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CentroDerm GmbH Research network |
| Locations | 1 site (Wuppertal, North Rhine-Westphalia) |
| Trial ID | NCT06648447 on ClinicalTrials.gov |
What this trial studies
This is an observational, non-interventional project following adults who receive in-label topical tirbanibulin (Klisyri) for facial or scalp actinic keratoses. Proliferation patterns will be measured at defined time points using line-field optical coherence tomography (LC-OCT), and optional dermatohistopathology may be performed at the end of treatment. Local skin reactions and tolerability will be recorded during follow-up visits. Eligible participants must have at least one non-hypertrophic, non-hyperkeratotic Olsen Grade I AK with a PRO II or III proliferation score and already be planned for Klisyri treatment independent of study enrollment.
Who should consider this trial
Good fit: Adults (≥18 years) in good general health with at least one non-hyperkeratotic, non-hypertrophic facial or scalp AK (Olsen Grade I) classified as PRO II or III and who are already scheduled to receive Klisyri are ideal candidates.
Not a fit: Patients with hypertrophic or hyperkeratotic lesions, AK outside the face or scalp, those not using Klisyri, or those with known intolerance to Klisyri are unlikely to benefit from this observation.
Why it matters
Potential benefit: If successful, the findings could help show that tirbanibulin reduces downward proliferation and inform treatment choices to lower recurrence risk.
How similar studies have performed: Tirbanibulin has demonstrated efficacy for actinic keratoses in prior clinical trials, but specifically tracking downward-directed proliferation with LC-OCT is a novel element of this work.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * male, female, diverse patients (\> 18yo) who are capable of giving consent * female patients are eligible if the patient is not a woman of childbearing potential (WOCBP) or if she is postmenopausal (cessation of menstruation \>12 months) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, total hysterectomy) * signed informed consent * diagnosis of at least 1 non-hypertrophic, non-hyperkeratotic actinic keratosis of the scalp or face with Olsen Grade I and PRO II or III * planned treatment of AK with Klisyri® before study start and indepently of the study * the study participant is in good general condition for his or her age and does not currently have any active diseases that, in the opinion of the investigator, justify exclusion from the study Exclusion Criteria: * known or documented intolerance to any of the ingredients of Klisyri® * any planned AK treatment other than Klisyri® in the treatment area * treatment of actinic keratoses in the treatment area within the past 3 Months (e.g. photodynamic therapy, topical 5-FU, diclofenac, imiquimod, cryotherapy etc.) * suspected invasive squamous cell cancer in the treatment area * chronic wounds, erosions, pre-existing inflamed or infected skin with disruption of the epidermal barrier in the treatment area * suspected non-compliance * current or within the last 8 weeks given systemic cancer medication * any other topical treatment against actinic keratosis in the treatment area within the past 12 weeks * any contraindication according to the Summary of Product Characteristics (SmPC) of Klisyri® * any systemic immunosuppressant given within the 8 weeks prior to the study (e.g. systemic prednisolone, azathioprine etc.) * locally applied retinoids, steroids, or other prescribed externals in the 4 weeks prior to the start of the study in the treatment area that, in the opinion of the study physician, necessitate exclusion * products containing glycolic or alpha-hydroxy acids applied locally in the treatment area in the last 4 weeks * chemical peelings in the treatment area in the last 4 weeks * simultaneous participation in a clinical trial * participation in a clinical study within the last 30 days * family members or colleagues of the investigator or the investigational team or the CRO * patient is in a position or has a relationship with the investigator that presents a potential conflict of interest
Where this trial is running
Wuppertal, North Rhine-Westphalia
- CentroDerm — Wuppertal, North Rhine-Westphalia, Germany (Recruiting)
Study contacts
- Study coordinator: Thomas Dirschka, Prof. Dr. med.
- Email: T.dirschka@centroderm.de
- Phone: +49(0)20262933736
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.